There is still plenty of unmet need in US laboratories for new molecular testing equipment, according to a new Kalorama Information market research report "Who’s Doing What in Molecular Diagnostics? – The Results of the Kalorama Information/Emmes Group Survey of U.S. Laboratories," based on a 2008 survey of 1000 interviews with hospital, research, and other laboratories.
More than half of labs interviewed indicated that they desired to add tests that they do not currently offer. Tests for Methicillin Resistant Staphylococcus Aureus (MRSA) top the list, desired by thirty-five percent of respondents, HSV and HPV and fifty-five other molecular tests also make the respondents’ ‘wish lists.’
"Labs would like to have more tests than they currently offer," said Shara Rosen, diagnostic analyst for Kalorama Information. "The data indicates that there is still significant potential for molecular tests for infectious diseases and hospital acquired infections."
The survey data also reveals significant information about the penetration of molecular tests outside of the infectious disease category, the prevalence of ‘homebrew’ tests, and company market share positions.
"No other company has molecular diagnostic product depth similar to that of Roche Diagnostics," Rosen said. "But a number of other companies, including Gen-Probe, Becton Dickinson, Qiagen, and Cepheid, are making inroads."
The survey was conducted by Boston and San Francisco-based Emmes Group and the results were analyzed by Kalorama Information’s senior market analyst Shara Rosen. Emmes Group’s representative survey reached fourteen percent of the US hospital market.
Kalorama Information’s new report, "Who’s Doing What in Molecular Diagnostics? – The Results of the Kalorama Information/Emmes Group Survey of U.S. Laboratories," summarizes and analyzes the results of the Emmes 2008 Molecular Testing Database.
Source: Kalorama Information
